About alterity therapeutics - ATHE
Alterity Therapeutics Ltd. engages in the business of research and development of therapeutic drugs designed to treat neurodegenerative diseases, focusing on Parkinsonian and other movement disorders. Its lead candidate, ATH434, is an oral small molecule drug designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. The company was founded by Geoffrey Paul Kempler on November 11, 1997 and is headquartered in Melbourne, Australia.
ATHE At a Glance
Alterity Therapeutics Ltd.
500 Collins Street
Melbourne, Victoria (VIC) 3000
| Phone | 61-3-9349-4906 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -15,857,019.86 | |
| Sector | Health Technology | Employees | 11 | |
| Fiscal Year-end | 06 / 2027 | |||
| View SEC Filings |
ATHE Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 3.288 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -3.57 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.002 |
ATHE Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,441,547.26 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
ATHE Liquidity
| Current Ratio | 14.52 |
| Quick Ratio | 14.52 |
| Cash Ratio | 11.824 |
ATHE Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -51.114 |
| Return on Equity | -55.262 |
| Return on Total Capital | -53.33 |
| Return on Invested Capital | -55.114 |
ATHE Capital Structure
| Total Debt to Total Equity | 0.453 |
| Total Debt to Total Capital | 0.451 |
| Total Debt to Total Assets | 0.42 |
| Long-Term Debt to Equity | 0.324 |
| Long-Term Debt to Total Capital | 0.322 |